SAB announces $22 million in investment

Dec. 28, 2018

SAB Biotherapeutics has raised $22 million in its Series A-2 round, which closed Dec. 15.

The Sioux Falls clinical stage biopharmaceutical development company plans to use the capital to accelerate its growth, continue expansion of its operations and advance its novel immunotherapy platform.

“This investment provides a significant boost to our capital strategy as we proceed to Phase 2 clinical trials and accelerate development of commercial targets for type 1 diabetes, cancer and influenza,” said Eddie Sullivan, SAB’s president, CEO and co-founder.

SAB develops immunotherapies from its unique technology platform to create fully human immunoglobulins without human serum to transform the treatment and prevention of diseases.

The company is focused on cancer, autoimmune and infectious diseases targets.

“The oversubscribed raise will enable us to get further along with our pipeline and represents a tremendous amount of confidence in the team and the technology,” Sullivan said.

Earlier this month, South Dakota Equity Partners announced it had invested $1.05 million as part of the Series A-2 round. It marks the first investment made by the new private equity fund focused on South Dakota growth-stage companies.

Since 2014, the company has developed immunotherapies against more than a dozen targets, achieved 100 percent efficacy in pre-clinical testing, completed successful Phase 1 clinical trials, and secured substantial grants, contracts and in-kind services from collaborators, including the Biomedical Advanced Research and Development Authority, and the National Institutes of Health.

From inside SAB’s new ‘pharm,’ game-changing biopharmaceuticals are coming

SAB announces $22 million in investment

SAB Biotherapeutics has raised $22 million in its Series A-2 round, which closed Dec. 15.

News Tip

Have a business news item to share with us?

Scroll to top